Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Declines By 67.7%

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 3,200 shares, a decrease of 67.7% from the February 28th total of 9,900 shares. Based on an average daily trading volume, of 3,300 shares, the short-interest ratio is presently 1.0 days.

Clinuvel Pharmaceuticals Stock Performance

Shares of CLVLY opened at $7.63 on Thursday. Clinuvel Pharmaceuticals has a 12 month low of $6.80 and a 12 month high of $11.40. The stock has a fifty day moving average price of $7.44 and a 200 day moving average price of $8.32.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).